Sonnet BioTherapeutics, Inc. is a clinical-stage biopharmaceutical company using an FHAB™ platform to transport cytokine-based biologics via serum albumin to tumor and lymphatic tissues, aiming to improve delivery and safety. Its pipeline includes several cytokine-derived candidates, with lead programs SON‑1010 and SON‑1210 in early-stage clinical trials.